Brief: Nicox Receives Formulation Patent Extending

Nicox SA

03/02/2020 07:08

Feb 3 (Reuters) - Nicox SA  NCOX.PA :
    * NICOX RECEIVES FORMULATION PATENT EXTENDING  NCX 470 U.S.
PATENT
COVERAGE TO 2039
    * INITIATION OF FIRST OF TWO U.S. PHASE 3 CLINICAL TRIALS
("MONT
BLANC") IS EXPECTED BY END OF Q2 2020
    * END-OF-PHASE 2 MEETING WITH U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) IS SCHEDULED IN Q1 2020
    * NCX 470 IS COVERED BY A COMPOSITION OF MATTER PATENT UNTIL
2029,
WHICH IS POTENTIALLY ELIGIBLE FOR UP TO A 5-YEAR PATENT TERM
EXTENSION BASED ON PERIOD OF REGULATORY REVIEW

Source text for Eikon:  ID:nGNE83rSwy 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))